Adding chest radiation to maintenance immunotherapy for extensive stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding radiation therapy to the chest after initial chemotherapy and immunotherapy can help keep extensive stage small cell lung cancer under control longer. It is designed for people whose cancer responded well to the first round of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have extensive stage small cell lung cancer (cancer that has spread widely in the lung or to other parts of the body).
- You must have already received 4 to 6 cycles of first-line chemotherapy combined with immunotherapy, and your scans must show the cancer has shrunk or stayed the same.
- You must be able to receive radiation therapy to the chest, based on your doctor's assessment.
- You must not have had radiation therapy to the chest before.
- You must not have a history of lung scarring (interstitial lung disease) or active lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
This study tests whether adding radiation to the chest area can improve the effectiveness of maintenance immunotherapy (atezolizumab) in patients with extensive-stage small cell lung cancer who have responded well to initial treatment.
This study tests a combination of three treatments for extensive-stage small cell lung cancer that has worsened after initial chemotherapy: an experimental pill, focused radiation (SBRT), and an immunotherapy drug. The goal is to see if this triple therapy can help the immune system fight the cancer more effectively.
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.